OtezlaTM（阿普瑞司特 30 毫克片剂）。

Skinmed Pub Date : 2024-08-02 eCollection Date: 2024-01-01

William Abramovits, Aditya K Gupta, Kimberly Dawn Vincent

{"title":"OtezlaTM（阿普瑞司特 30 毫克片剂）。","authors":"William Abramovits, Aditya K Gupta, Kimberly Dawn Vincent","doi":"","DOIUrl":null,"url":null,"abstract":"OtezlaTM was first approved on March 21, 2014 for the treatment of psoriatic arthritis, on September 23, 2014 for moderate to severe plaque psoriasis and on July 19, 2019 for the treatment of oral ulcers associated with Behcet's disease (BD). Apremilast is an inhibitor of phosphodi-esterase-4, an enzyme involved in the pathogenesis of several dermatologic conditions. This review explores the potential utility of apremilast in the treatment of other unapproved dermatologic indications.","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"OtezlaTM (Apremilast 30-Mg Tablets).\",\"authors\":\"William Abramovits, Aditya K Gupta, Kimberly Dawn Vincent\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"OtezlaTM was first approved on March 21, 2014 for the treatment of psoriatic arthritis, on September 23, 2014 for moderate to severe plaque psoriasis and on July 19, 2019 for the treatment of oral ulcers associated with Behcet's disease (BD). Apremilast is an inhibitor of phosphodi-esterase-4, an enzyme involved in the pathogenesis of several dermatologic conditions. This review explores the potential utility of apremilast in the treatment of other unapproved dermatologic indications.\",\"PeriodicalId\":94206,\"journal\":{\"name\":\"Skinmed\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skinmed\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skinmed","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

OtezlaTM于2014年3月21日首次获批用于治疗银屑病关节炎，2014年9月23日获批用于治疗中度至重度斑块状银屑病，2019年7月19日获批用于治疗与白塞氏病（BD）相关的口腔溃疡。阿普瑞司特是磷酸二酯酶-4的抑制剂，磷酸二酯酶-4参与了多种皮肤病的发病机制。本综述探讨了阿普瑞司特在治疗其他未经批准的皮肤病适应症方面的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Otezla^TM (Apremilast 30-Mg Tablets).

Otezla^TM was first approved on March 21, 2014 for the treatment of psoriatic arthritis, on September 23, 2014 for moderate to severe plaque psoriasis and on July 19, 2019 for the treatment of oral ulcers associated with Behcet's disease (BD). Apremilast is an inhibitor of phosphodi-esterase-4, an enzyme involved in the pathogenesis of several dermatologic conditions. This review explores the potential utility of apremilast in the treatment of other unapproved dermatologic indications.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Skinmed

自引率

0.00%

发文量